Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperparathyroidism, Secondary Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Renal Osteodystrophy, End Stage Renal Disease
Interventions
calcitriol, growth hormone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
1 Year to 18 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
Interventions
Zemplar® injection, Hectorol® injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Bellevue, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 23, 2009 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 110 Years
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
68
States / cities
Birmingham, Alabama • Alhambra, California • Azusa, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Interventions
DP001 softgel capsules, Placebo
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
8
States / cities
Downey, California • Paramount, California • Hudson, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
Interventions
Paricalcitol, Cinacalcet
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Interventions
Cinacalcet hydrochloride, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 2189 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
Interventions
cinacalcet capsule, placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP201 Injection, Doxercalciferol
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced May 22, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced May 22, 2026, 4:14 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
Interventions
Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Cinacalcet, Oral Placebo, Intravenous Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
41
States / cities
Azusa, California • Bakersfield, California • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Kidney Failure, Secondary Hyperparathyroidism, Hyperphosphatemia, Hypercalcemia
Interventions
Calcitriol, Paricalcitol
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Renal Disease
Interventions
paricalcitol injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Cinacalcet
Drug
Lead sponsor
Amgen
Industry
Eligibility
Up to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Tucker, Georgia • Baltimore, Maryland + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
45
States / cities
Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
Interventions
Calcifediol Oral Capsule, Placebo oral capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
18
States / cities
Peoria, Arizona • Phoenix, Arizona • Cypress, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced May 22, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Hypocalcemia
Interventions
Calcitriol
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Cinacalcet, active vitamin D analogue
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Interventions
[¹⁴C]Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced May 22, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Teriparatide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Vitamin D Deficiency, Secondary Hyperparathyroidism, Obesity
Interventions
Ergocalciferol, Cholecalciferol
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced May 22, 2026, 4:14 AM EDT